Fundamental Analysis of PROCESSA PHARMACEUTICALS INC(NASDAQ:PCSA) stock

Fundamental Rating

PCSA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While PCSA seems to be doing ok healthwise, there are quite some concerns on its profitability. PCSA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

PCSA had negative earnings in the past year.

PCSA had a negative operating cash flow in the past year.

PCSA had negative earnings in each of the past 5 years.

PCSA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -233.23%, PCSA is doing worse than 91.62% of the companies in the same industry.

PCSA has a worse Return On Equity (-309.78%) than 75.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-233.23%
ROE	-309.78%
ROIC	N/A

ROA(3y)-184.5%

ROA(5y)-132.91%

ROE(3y)-211.61%

ROE(5y)-153.21%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PCSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PCSA has more shares outstanding than it did 1 year ago.

PCSA has more shares outstanding than it did 5 years ago.

PCSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -29.30, we must say that PCSA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of PCSA (-29.30) is worse than 89.53% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that PCSA is not too dependend on debt financing.

The Debt to Equity ratio of PCSA (0.00) is better than 61.26% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-29.3

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.97 indicates that PCSA has no problem at all paying its short term obligations.

PCSA has a Current ratio of 3.97. This is comparable to the rest of the industry: PCSA outperforms 58.64% of its industry peers.

A Quick Ratio of 3.97 indicates that PCSA has no problem at all paying its short term obligations.

With a decent Quick ratio value of 3.97, PCSA is doing good in the industry, outperforming 60.73% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.97
Quick Ratio	3.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PCSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.69%, which is quite impressive.

EPS 1Y (TTM)78.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.63%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

PCSA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.34% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y55.53%

EPS Next 2Y32.31%

EPS Next 3Y8.31%

EPS Next 5Y28.34%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCSA. In the last year negative earnings were reported.

Also next year PCSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.31%

EPS Next 3Y8.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PCSA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (12/18/2024, 5:02:18 PM)

After market: 0.9244 -0.02 (-1.93%)

0.9426

-0.07 (-6.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.08M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-233.23%
ROE	-309.78%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.97
Quick Ratio	3.97
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)78.69%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y55.53%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROCESSA PHARMACEUTICALS INC (PCSA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens